SNDX Syndax Pharmaceuticals Inc.

5.18
-0.1  -2%
Previous Close 5.28
Open 5.33
Price To Book 2
Market Cap 128650226
Shares 24,835,951
Volume 178,735
Short Ratio
Av. Daily Volume 250,761

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 1Q 2019.
Entinostat plus Tecentriq - ENCORE 603
Ovarian cancer
Phase 2 top-line data due 2Q 2019.
Entinostat plus Tecentriq - ENCORE 602
Triple negative breast cancer (TNBC)
Phase 2 updated data to be presented September 24, 2018 did not meet prespecified ORR endpoint.
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC), colorectal cancer
Phase 3 PFS date did not meet primary endpoint - October 25, 2018. OS data due 2Q 2019.
E2112
HR+, HER2- breast cancer
Phase 1 poster at ASCO June 2018.
Entinostat
Solid tumors
Phase 1 initial data due 2H 2019.
SNDX-6352
Chronic graft versus host disease
Phase 1b/2 trial to be initiated 2Q 2019.
Entinostat plus NKTR-214 - ENCORE 606
Melanoma

Latest News

  1. Syndax Highlights 2019 Clinical and Corporate Outlook
  2. Can We See Significant Institutional Ownership On The Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Share Register?
  3. Edited Transcript of SNDX earnings conference call or presentation 5-Nov-18 9:30pm GMT
  4. Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting
  5. Investor Expectations to Drive Momentum within CommScope Holding, AMC Networks, Henry Schein, Lindblad Expeditions, Apple Hospitality REIT, and Syndax Pharmaceuticals — Discovering Underlying Factors of Influence
  6. Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
  7. Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update
  8. Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting
  9. Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018
  10. The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default
  11. Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer
  12. Syndax to Present at the 2018 Cantor Global Healthcare Conference
  13. Syndax Announces Changes to its Board of Directors
  14. Do Options Traders Know Something About Syndax (SNDX) Stock We Don't?
  15. The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering
  16. Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
  17. Are Syndax Pharmaceuticals Inc’s (NASDAQ:SNDX) Interest Costs Too High?
  18. Edited Transcript of SNDX earnings conference call or presentation 7-Aug-18 8:30pm GMT
  19. Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer